These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24766732)

  • 1. Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer.
    Belani CP; Yamamoto N; Bondarenko IM; Poltoratskiy A; Novello S; Tang J; Bycott P; Niethammer AG; Ingrosso A; Kim S; Scagliotti GV
    BMC Cancer; 2014 Apr; 14():290. PubMed ID: 24766732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.
    Yu H; Zhang J; Wu X; Luo Z; Wang H; Sun S; Peng W; Qiao J; Feng Y; Wang J; Chang J
    Cancer Biol Ther; 2014 Jul; 15(7):832-9. PubMed ID: 24755888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer.
    Bondarenko IM; Ingrosso A; Bycott P; Kim S; Cebotaru CL
    BMC Cancer; 2015 May; 15():339. PubMed ID: 25929582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.
    Chen H; Modiano MR; Neal JW; Brahmer JR; Rigas JR; Jotte RM; Leighl NB; Riess JW; Kuo CJ; Liu L; Gao B; Dicioccio AT; Adjei AA; Wakelee HA
    Br J Cancer; 2014 Feb; 110(3):602-8. PubMed ID: 24292447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer.
    Mubarak N; Gaafar R; Shehata S; Hashem T; Abigeres D; Azim HA; El-Husseiny G; Al-Husaini H; Liu Z
    BMC Cancer; 2012 Sep; 12():423. PubMed ID: 23006447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
    Doebele RC; Spigel D; Tehfe M; Thomas S; Reck M; Verma S; Eakle J; Bustin F; Goldschmidt J; Cao D; Alexandris E; Yurasov S; Camidge DR; Bonomi P
    Cancer; 2015 Mar; 121(6):883-92. PubMed ID: 25377507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
    Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
    Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
    Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
    Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
    Scagliotti GV; Felip E; Besse B; von Pawel J; Mellemgaard A; Reck M; Bosquee L; Chouaid C; Lianes-Barragán P; Paul EM; Ruiz-Soto R; Sigal E; Ottesen LH; Lechevalier T
    J Thorac Oncol; 2013 Dec; 8(12):1529-37. PubMed ID: 24389434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.
    Schmid-Bindert G; Gebbia V; Mayer F; Arriola E; Márquez-Medina D; Syrigos K; Biesma B; Leschinger MI; Frimodt-Moller B; Ripoche V; Myrand SP; Nguyen TS; Hozak RR; Zimmermann A; Visseren-Grul C; Schuette W
    Lung Cancer; 2013 Sep; 81(3):428-434. PubMed ID: 23790468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Pujol JL; Paz-Ares L; de Marinis F; Dediu M; Thomas M; Bidoli P; Corral J; San Antonio B; Chouaki N; John W; Zimmermann A; Visseren-Grul C; Gridelli C
    Clin Lung Cancer; 2014 Nov; 15(6):418-25. PubMed ID: 25104617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
    Barlesi F; Scherpereel A; Rittmeyer A; Pazzola A; Ferrer Tur N; Kim JH; Ahn MJ; Aerts JG; Gorbunova V; Vikström A; Wong EK; Perez-Moreno P; Mitchell L; Groen HJ
    J Clin Oncol; 2013 Aug; 31(24):3004-11. PubMed ID: 23835708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.
    Kozloff MF; Martin LP; Krzakowski M; Samuel TA; Rado TA; Arriola E; De Castro Carpeño J; Herbst RS; Tarazi J; Kim S; Rosbrook B; Tortorici M; Olszanski AJ; Cohen RB
    Br J Cancer; 2012 Oct; 107(8):1277-85. PubMed ID: 22990652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
    Paz-Ares LG; Altug S; Vaury AT; Jaime JC; Russo F; Visseren-Grul C
    BMC Cancer; 2010 Mar; 10():85. PubMed ID: 20211022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer.
    Cohen MH; Justice R; Pazdur R
    Oncologist; 2009 Sep; 14(9):930-5. PubMed ID: 19737998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.
    Buikhuisen WA; Scharpfenecker M; Griffioen AW; Korse CM; van Tinteren H; Baas P
    J Thorac Oncol; 2016 May; 11(5):758-768. PubMed ID: 26845191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer.
    Ahn MJ; Yang JC; Liang J; Kang JH; Xiu Q; Chen YM; Blair JM; Peng G; Linn C; Orlando M
    Lung Cancer; 2012 Aug; 77(2):346-52. PubMed ID: 22534669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.